Clinical Trials Logo

Clinical Trial Summary

With the rapid spread of COVID-19 (SARS-CoV-2) disease all over the world and the announcement of a pandemic, research on many different drug approaches has begun and these researches continue today. Although measures such as social distance, quarantine and isolation are effective in reducing the spread of SARS-CoV-2 in the short term during the pandemic, there is no effective treatment method yet. It is known that especially healthcare workers, the elderly and individuals with underlying health problems are at high risk. However, gender differences in COVID-19 clinical outcomes are thought to exist, and there is growing evidence that the disease is more severe in men than in women and mortality rates are higher.With the global consensus that the most effective approach to control the COVID-19 pandemic is a vaccination that is effective in COVID-19, vaccines have been developed with many different methods. CoronaVac vaccine (inactivated + aluminum adjuvant vaccine) is a vaccine developed with the inactive method, which is the classic vaccine production method. After the completion of Phase 1 and Phase 2 trials of the vaccine, Phase 3 trials were initiated to investigate the effectiveness of the vaccine in 4 different countries, including Turkey. Emergency use approval has been given for the CoronaVac vaccine by Turkish Pharmaceuticals and Medical Devices Agency. Researching the effects of vaccination on oxidative stress parameters, trace element and quality of life levels in COVID-19 may provide useful information in determining the effects of COVID-19 vaccine. It is thought that the anti-inflammatory and antioxidant properties of some vitamins and trace elements may be associated with positive results in COVID-19 patients, and the physiological roles of these vitamins and trace elements in COVID-19 have been demonstrated by studies. It is important to investigate the levels of free radicals known to be effective in the development of cardiovascular disease due to oxidative stress, which can provide information on determining the risk of cardiovascular complications in the COVID-19 pandemic. In addition, the quality of life of individuals decreases in the COVID-19 pandemic.This study is planned to be carried out by including male individuals to be vaccinated in İzmir Bakırçay University Çiğli Training and Research Hospital. Determination of oxidative stress parameters, trace element levels and quality of life levels before and after vaccination applications to be applied to individuals within the scope of the study; It was planned to compare these data before and after vaccination. After analyzing the data obtained from the research with appropriate statistical methods, the data will be evaluated.


Clinical Trial Description

Coronavirus-2019 (COVID-19) is a global epidemic that has serious consequences and affects the world with its rapid spread and high mortality rate. The number of people infected with Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV2) is rapidly increasing. COVID-19 patients may have pneumonia, severe symptoms of Acute Respiratory Distress Syndrome (ARDS) and multiple organ failure, as well as cases with no symptoms. Although social distance, quarantine and isolation are effective in reducing the spread of SARS-CoV-2 in the short term during the pandemic, there is no effective treatment method yet. It is known that especially healthcare workers, the elderly and individuals with underlying health problems are at high risk. However, gender differences in COVID-19 clinical outcomes are thought to exist, and there is growing evidence that the disease is more severe in men than in women and mortality rates are higher. The highly contagious nature of SARS-CoV-2 has led to millions of cases worldwide, strengthening the global need for an effective vaccine to halt the spread of the disease and reduce the number of deaths. With the global consensus that the most effective approach to control the COVID-19 pandemic is a vaccination that is effective in COVID-19, many different vaccines have been tested with the acceleration of vaccination studies. According to the data of the World Health Organization, there are 236 vaccines in total, with clinical (63) and pre-clinical (173) studies developed using 10 different methods. Types of vaccines for COVID-19 include conventionally live attenuated viruses, inactivated virus protein or polysaccharide conjugated subunit vaccines, virus-like particles (VLPs), nucleic acid (DNA and RNA), viral vectors (replicating and non-replicating), and and other vaccines consisting of recombinant proteins. Although the production of virus-based vaccines takes longer than other vaccines, the immune response is expected to be at a good level. Measles, mumps, Hepatitis A and chickenpox vaccines are examples of vaccines developed with the virus-based method. CoronaVac vaccine (inactivated + aluminum adjuvant vaccine) is a vaccine developed by the inactive method (produced and inactivated by the SARS-CoV-2 virus in the laboratory), which is the classic vaccine production method. China-based vaccine development Sinovac Biotech Ltd. Made by the biopharmaceutical company named. After the completion of Phase 1 and Phase 2 studies of the vaccine, Phase 3 studies were initiated to investigate the effectiveness of the vaccine in 4 different countries, including our country. Emergency use approval has been given for the CoronaVac vaccine by Turkish Pharmaceuticals and Medical Devices Agency. The clinical picture of COVID-19 can be heterogeneous, ranging from asymptomatic to severe disease, which can be associated with a cytokine storm. The pathogenesis of COVID-19 is not fully understood, but is likely multifactorial and, in severe cases, with a systemic hyperinflammatory response and associated thromboembolic complications. Some vitamins and nutrients may be beneficial for patients infected with COVID-19 due to their anti-inflammatory and antioxidant properties. Vitamins such as A, B, C, D, E and folate, and trace elements such as iron, zinc, magnesium, selenium and copper play important roles in supporting both innate and adaptive immune systems. Free radicals are continuously formed at the active site of enzymes as intermediates in enzymatic reactions occurring during cell metabolism. Reactive oxygen species and reactive nitrogen, known as intermediates, sometimes leak from the active site of enzymes and accidentally interact with molecular oxygen and form free oxygen radicals. Lipids, proteins, enzymes, carbohydrates, and DNA can be damaged due to oxidative stress, random breaks and bonds in DNA chains may occur as a result of damage to membranes, damage to enzymes and structural proteins may result in cell death, and these phenomena may result in cancer, neurodegenerative and cardiovascular diseases, diabetes and It constitutes the molecular basis in the development of autoimmune disorders. With the quarantine measures applied, not going out and staying at home causes the person to stay away from his daily routine life, the increase in the time spent at home, the pandemic news that is constantly being listened to and watched cause increasing anxiety, causing both changes in mood and a more sedentary life . Studies have also reported that negative psychological effects such as post-traumatic stress symptoms, confusion and anger as a result of quarantine have been reported. In addition, it has been said that restriction often causes boredom, disappointment and a feeling of isolation. These consequences, brought about by the COVID-19 pandemic, negatively affect the quality of life of individuals. During the COVID-19 pandemic, it has been reported that the depression and anxiety levels of healthcare workers increased and their quality of life decreased. The objective of this study is to compare and determined and the changes of oxidative stress parameters, trace element and quality of life levels in healthy men just before the first dose of COVID-19 vaccine and on the 7th day after the second dose of COVID19 vaccine. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04751695
Study type Interventional
Source Izmir Bakircay University
Contact
Status Not yet recruiting
Phase N/A
Start date February 2021
Completion date April 2021

See also
  Status Clinical Trial Phase
Completed NCT05049226 - Third Dose Vaccination With AstraZeneca or Pfizer COVID-19 Vaccine Among Adults Received Sinovac COVID-19 Vaccine Phase 2
Recruiting NCT05998824 - COVID-19 Vaccination Hesitancy in Adults With Sickle Cell Disease N/A
Recruiting NCT05097053 - A Heterologous 3rd COVID-19 Vaccine of MVC-COV1901 to Evaluate Immunogenicity and Safety in Adults With ChAdOx1-nCov-19 Phase 4
Active, not recruiting NCT05463419 - A Phase II/III Study of PIKA Recombinant SARS-CoV-2 Vaccine as a Booster Dose. Phase 2/Phase 3
Active, not recruiting NCT05293223 - Phase IIB Study of Recombinant Novel Coronavirus Vaccine Phase 2
Completed NCT04691947 - Safety and Immunogenicity of Two Different Strengths of the Inactivated COVID-19 Vaccine ERUCOV-VAC Phase 1
Completed NCT05288231 - Cardiac Manifestation in Adolescent After Pfizer COVID-19 Injection in Thailand
Completed NCT04546841 - Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in Adults Phase 1
Recruiting NCT04963790 - Enabling Family Physicians to Reduce Vaccine Hesitancy and Increase Covid-19 Vaccine Uptake N/A
Completed NCT05216601 - A Study to Evaluate the Safety, Tolerability, and Immunogenicity of MVC-COV1901 or MVC-COV1901(Beta) Against COVID-19 Phase 1
Completed NCT04566276 - ChulaCov19 Vaccine in Healthy Adults Phase 1/Phase 2
Completed NCT04915820 - Iron and COVID-19 Vaccine Response N/A
Completed NCT05268679 - Covid-19 Vaccine Response in Heart Transplant Recipients
Completed NCT04898946 - Serological Response to mRNA and Inactivated COVID-19 Vaccine in Health Care Workers in Hong Kong
Recruiting NCT05869968 - SCIVAX: Biomarkers of Immune Dysfunction and Vaccine Responsiveness in Chronic SCI
Active, not recruiting NCT05197712 - Evaluation of the Safety, Tolerability, and Reactogenicity of the Baiya SARS-CoV-2 Vax 2 Vaccine for COVID-19 Disease Phase 1
Recruiting NCT05553743 - Researchers at UC San Diego Are Learning About the Benefits of Human Milk and How it Influences Infant and Child Health
Active, not recruiting NCT05188469 - Study to Assess the Safety, Tolerability and Explore the Immunogenicity of EG-COVID and EG-COVARo in Healthy Adult Volunteers Phase 1/Phase 2
Completed NCT04764422 - Assess the Safety and Immunogenicity of NDV-HXP-S Vaccine in Thailand Phase 1/Phase 2
Recruiting NCT04838080 - Safety and Immunogenicity of the Inactivated Koçak-19 Inaktif Adjuvanlı COVID-19 Vaccine Compared to Placebo Phase 1